1.Clinical Significance
The majority of patients with diffuse large B-cell lymphoma (DLBCL) achieve remission following first-line therapy. However, up to 40% of patients experience disease recurrence, partially due to the persistence of low levels of measurable residual disease (MRD) that are difficult to detect with standard imaging methods1,2. Early identification of patients at high risk of recurrence during therapy helps develop risk-adapted treatment strategies to improve survival.
Regular MRD monitoring during and after treatment can provide the best insights into long-term patient prognosis1,3.
MRD detection can more accurately predict long-term prognosis. In a retrospective study, circulating tumor DNA (ctDNA) was measured using immunoglobulin next-generation sequencing (IgNGS) to evaluate the treatment efficacy in previously untreated DLBCL patients who received EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) with or without rituximab. Patients with MRD negativity during treatment had significantly extended progression-free survival (PFS), lasting up to 20 years1.

Compared to traditional PET and/or CT scans, IgNGS can detect disease at levels undetectable by imaging, allowing earlier identification of recurrence and reducing false-positive results, thereby providing clearer therapeutic decisions for patients.
Limitations of PET and/or CT Scans:
These imaging modalities are qualitative in nature, making it difficult to accurately assess the extent of disease burden changes. Additionally, they carry risks of radiation exposure and false positives1,4,5.
Advantages of IgNGS-MRD:
1. Earlier Detection of Disease Recurrence:Studies have shown that IgNGS can detect disease recurrence an average of 3.5 months earlier (range 0-200 months) than imaging modalities1.

2. Fewer False-Positive Results:Studies have shown that the positive predictive value (PPV) of IgNGS is 88.2%, while the PPV of imaging is less than 40%. This means that the majority of positive PET/CT scans are not true recurrences1,6,7.
By monitoring MRD levels, doctors can assess the efficacy of CAR T-cell therapy and bispecific antibody therapies and predict long-term patient outcomes. This provides crucial insights for tailoring individualized treatment plans, helping to improve survival rates and quality of life for DLBCL patients8.
CAR T-Cell Therapy:

Research has shown that IgNGS-MRD can predict treatment efficacy as early as one week after CAR T-cell infusion. By day 28 post-treatment, all patients who achieved durable remission were MRD-negative. Additionally, ctDNA detection at day 28 can help predict the risk of subsequent progression in patients with imaging-assessed partial response (PR) or stable disease (SD)8.
This demonstrates that IgNGS-MRD enables doctors to evaluate the effectiveness of CAR-T cell therapy earlier and devise follow-up treatment plans.
Bispecific Antibody Therapy: Studies have found that among patients who were ctDNA-negative during treatment, approximately 78.7% remained MRD-negative at 6 months. Patients who achieved MRD-negativity during treatment had significantly longer progression-free survival (PFS) compared to those who remained MRD-positive9.

This indicates that IgNGS can assist doctors in assessing the long-term efficacy of bispecific antibody therapy and predicting patient prognosis.
Microscopic residual disease (MRD) detection holds significant clinical value in patients with diffuse large B-cell lymphoma (DLBCL) before and after autologous stem cell transplantation. In a study of patients with relapsed/refractory DLBCL, MRD was detected in 23% of peripheral blood stem cell samples before transplantation. Compared to samples that were MRD-negative as detected by IgNGS, these MRD-positive samples were associated with shorter progression-free survival (PFS) and overall survival (OS). The study found that patients with MRD-positive status before transplantation had a 2.9-fold and 2.0-fold reduction in 5-year PFS and OS, respectively 10, 11.

MRD testing can help doctors assess the prognosis of DLBCL patients and tailor individualized treatment plans based on MRD test results, thereby improving patients' survival rates and quality of life.
Before ASCT, MRD-positive patients may require more aggressive pre-treatment regimens or adjuvant therapies.
After ASCT, MRD-positive patients may need closer monitoring and earlier intervention measures.
2. Timing of MRD Testing in the Treatment Process of DLBCL

3.Shenzhen Neoimmune Co., Ltd Lymphoma MRD Detection Product
The detection method of Shenzhen Neoimmune Co., Ltd's lymphoma MRD detection product is based on a highly accurate approach that combines multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) technologies. It utilizes B/T cell receptor gene-specific primers to precisely amplify and enrich target regions. Through NGS, we perform deep sequencing of the target region libraries and, in combination with bioinformatics analysis software, comprehensively analyze the sequencing data. This detection method boasts high sensitivity, high specificity, and high accuracy, providing robust support for the early diagnosis, treatment monitoring, and prognosis evaluation of lymphoma.
(1) Detection Content
The B-cell receptor genes include IGH (V-D-J rearrangement and D-J rearrangement), IGK (V-J rearrangement, Intron-Kde, V-Kde rearrangement), and IGL (V-J rearrangement);
The T-cell receptor genes include TRB (V-D-J rearrangement).

(2)Applicable Population
All patients with non-Hodgkin lymphoma (must be able to provide a tumor tissue sample).
(3)Sample Requirements

(4)Testing Process
The testing cycle is 10 natural days.

References
1. Roschewski M, et al. Lancet Oncol. 2015;16(5):541-549.
2. Hu R, et al. Curr Oncol Rep. 2019;21(5):44.
3. Kurtz D, et al. Blood. 2015;125(24):3679-3687.
4. Suh K, et al. Korean J Intern Med. 2019;34(4):894-901.
5. Carr R, et al. J Nucl Med. 2014;55(12):1936-1944.
6. Avivi I, et al. Am J Hematol. 2013;88(5):400-405.
7. El-Galaly T, et al. Leuk Lymphoma. 2011;52(4):597-603.
8. Frank M, et al. J Clin Oncol. 2021;39(27):3034-3043.
9. Thieblemont C, et al. J Clin Oncol. 2023;41(12):2238-2247.
10. Merryman R, et al. Blood. 2020;136:22.
11. Merryman R, et al. Blood Adv. 2023;7(17):4748-4759.